Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Deshayes

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
JACC. Cardiovascular Imaging|October 13, 2014
Quantification of myocardial blood flow in absolute terms using (82)Rb PET imaging: the RUBY-10 StudySergey V Nesterov, Emmanuel Deshayes, Roberto Sciagrà, et al.
The Lancet. Oncology|June 1, 2026
[<sup>177</sup>Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trialEric Baudin, Alice Durand, Amandine Beron, et al.
Lancet (London, England)|July 2, 2026
[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trialThomas Walter, Henning Jann, Catherine Ansquer, et al.
BMC Cancer|April 4, 2025
A Randomized clinical trial evaluating the impact on survival and quality of life of <sup>177</sup>Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)Jaume Capdevila, Virginia Pubul, Urbano Anido, et al.
Journal for Immunotherapy of Cancer|February 6, 2019
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodiesYahya Ashraf, Hanane Mansouri, Valérie Laurent-Matha, et al.
BMC Cancer|June 13, 2026
Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)Jaume Capdevila, Virginia Pubul, Urbano Anido, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
JACC. Cardiovascular Imaging|October 13, 2014
Quantification of myocardial blood flow in absolute terms using (82)Rb PET imaging: the RUBY-10 StudySergey V Nesterov, Emmanuel Deshayes, Roberto Sciagrà, et al.
The Lancet. Oncology|June 1, 2026
[<sup>177</sup>Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trialEric Baudin, Alice Durand, Amandine Beron, et al.
Lancet (London, England)|July 2, 2026
[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trialThomas Walter, Henning Jann, Catherine Ansquer, et al.
BMC Cancer|April 4, 2025
A Randomized clinical trial evaluating the impact on survival and quality of life of <sup>177</sup>Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)Jaume Capdevila, Virginia Pubul, Urbano Anido, et al.
Journal for Immunotherapy of Cancer|February 6, 2019
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodiesYahya Ashraf, Hanane Mansouri, Valérie Laurent-Matha, et al.
BMC Cancer|June 13, 2026
Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)Jaume Capdevila, Virginia Pubul, Urbano Anido, et al.
Pageof 8